Please login to the form below

Not currently logged in
Email:
Password:

Agreement to develop depression treatment

Marco Polo Pharmaceuticals and Biocortech are to develop BC-19 in treatment-resistant depression

Luxembourg-based Marco Polo Pharmaceuticals, has entered into a licensing agreement with French diagnostics company, Biocortech, to develop BC-19 in treatment-resistant depression. Under the terms of the agreement, Marco Polo takes responsibility for all further clinical development of BC-19 and for eventual commercialisation or outlicensing to a suitable partner.

BC-19 is an eburnamine derivative, previously investigated for the indications of cerebral insufficiency and cognitive deficits. As an antidepressant, it showed benefits when administered to patients suffering from treatment-resistant depression.

Moreover, BC19 offers the possibility of disease modification by restoring the function of deficient noradrenergic pathways, which terminate in the prefrontal cortex.

"It is a great accomplishment for our company to announce a licensing agreement of this kind," said Prof Mondher Toumi, CEO of Marco Polo Pharmaceuticals.

The company's chief medical officer, Dr Aleksandar Bakhutshuili, added: "There is a major unmet need in resistant and melancholic depression, and we believe that this compound will help those who suffer from this disease. Our team looks forward to further developing BC-19 in these indications."

"This agreement, which is aligned with our strategic shift toward biomarkers, is a great opportunity to move BC-19 development forward and to bring a novel class of promising compounds to patients," said Dr Dinah Weissmann, CEO of Biocortech.

Treatment-resistant depression is a common manifestation of major depressive disorder, where patients do not respond to adequate courses of at least two different antidepressants. It is estimated that 10-30 per cent of cases are either partially or totally resistant to antidepressant therapy.

Marco Polo Pharmaceuticals is a drug repositioning company that identifies, acquires and develops promising drug candidates in new indications or markets. It focuses on major central nervous system diseases.

Biocortech is a biopharmaceutical company working to discover and develop novel biomarkers for psychiatric disorders.

6th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics